169 related articles for article (PubMed ID: 33333978)
1. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor That Eliminates Unrestrained Proliferation of Breast Carcinoma Cells.
Alshiraihi IM; Jarrell DK; Arhouma Z; Hassell KN; Montgomery J; Padilla A; Ibrahim HM; Crans DC; Kato TA; Brown MA
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333978
[TBL] [Abstract][Full Text] [Related]
2. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Alnabulsi SM; Al-Shar'i NA
Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
[No Abstract] [Full Text] [Related]
3. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
[TBL] [Abstract][Full Text] [Related]
4. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
[TBL] [Abstract][Full Text] [Related]
5. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
Peserico A; Germani A; Sanese P; Barbosa AJ; Di Virgilio V; Fittipaldi R; Fabini E; Bertucci C; Varchi G; Moyer MP; Caretti G; Del Rio A; Simone C
J Cell Physiol; 2015 Oct; 230(10):2447-2460. PubMed ID: 25728514
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
[TBL] [Abstract][Full Text] [Related]
8. Enhanced SMYD3 expression is essential for the growth of breast cancer cells.
Hamamoto R; Silva FP; Tsuge M; Nishidate T; Katagiri T; Nakamura Y; Furukawa Y
Cancer Sci; 2006 Feb; 97(2):113-8. PubMed ID: 16441421
[TBL] [Abstract][Full Text] [Related]
9. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
10. Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.
Ren TN; Wang JS; He YM; Xu CL; Wang SZ; Xi T
Med Oncol; 2011 Dec; 28 Suppl 1():S91-8. PubMed ID: 20957523
[TBL] [Abstract][Full Text] [Related]
11. An Improved Protocol for the Virtual Screening Discovery of Novel Histone Deacetylase Inhibitors.
Song Q; Liu T; Liu Y; Wang S; Fan C; Zheng L; Bao Y; Sun L; Yu C; Sun Y; Song Z; Wang G; Huang Y; Li Y
Chem Pharm Bull (Tokyo); 2019 Oct; 67(10):1076-1081. PubMed ID: 31406093
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.
Parenti MD; Naldi M; Manoni E; Fabini E; Cederfelt D; Talibov VO; Gressani V; Guven U; Grossi V; Fasano C; Sanese P; De Marco K; Shtil AA; Kurkin AV; Altieri A; Danielson UH; Caretti G; Simone C; Varchi G; Bartolini M; Del Rio A
Eur J Med Chem; 2022 Dec; 243():114683. PubMed ID: 36116234
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of the Conformational Change of the Protein Methyltransferase SMYD3: A Molecular Dynamics Simulation Study.
Sun J; Li Z; Yang N
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281237
[TBL] [Abstract][Full Text] [Related]
14. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].
Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH
Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068
[TBL] [Abstract][Full Text] [Related]
15. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.
Fenizia C; Bottino C; Corbetta S; Fittipaldi R; Floris P; Gaudenzi G; Carra S; Cotelli F; Vitale G; Caretti G
Nucleic Acids Res; 2019 Feb; 47(3):1278-1293. PubMed ID: 30544196
[TBL] [Abstract][Full Text] [Related]
16. Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer.
Parbin S; Shilpi A; Kar S; Pradhan N; Sengupta D; Deb M; Rath SK; Patra SK
Mol Biosyst; 2016 Jan; 12(1):48-58. PubMed ID: 26540192
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Jiang Y; Lyu T; Che X; Jia N; Li Q; Feng W
J Cancer; 2019; 10(17):4072-4084. PubMed ID: 31417652
[No Abstract] [Full Text] [Related]
18. Structural Analysis of SMYD3 Lysine Methyltransferase for the Development of Competitive and Specific Enzyme Inhibitors.
Jarrell DK; Hassell KN; Alshiraihi I; Crans DC; Brown MA
Diseases; 2021 Dec; 10(1):. PubMed ID: 35076487
[TBL] [Abstract][Full Text] [Related]
19. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
[TBL] [Abstract][Full Text] [Related]
20. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]